Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Nanographene oxide (NGO) is a novel nano-wall material that tracks to tumors in vivo, and which, as a consequence of its large surface area, has the capacity to carry a large payload. This study explores the use of anti-HER2 antibody (trastuzumab)-conjugated NGO, radiolabeled with (111)In-benzyl-diethylenetriaminepentaacetic acid (BnDTPA) via ππ-stacking, for functional imaging. In two HER2-overexpressing murine models of human breast cancer, high tumor-to-muscle ratio was achieved, resulting in clear visualization of tumor using single-photon emission computed tomography (SPECT). In the BALB/neuT model and in BALB/c nu/nu mice bearing 231/H2N xenografts, tumor accumulation amounted to 12.7 ± 0.67 and 15.0 ± 3.7% of the injected dose/g (%ID/g) of tumor tissue at 72 h, with tumor-to-muscle ratios of 35:1 and 7:1, respectively. Radiolabeled NGO-trastuzumab conjugates demonstrated superior pharmacokinetics compared to radiolabeled trastuzumab without NGO, with more rapid clearance from the circulation. The use of NGO as a scaffold to build radiolabeled nano-immunoconstructs holds promise for molecular imaging of tumors.

Original publication

DOI

10.1016/j.biomaterials.2012.10.054

Type

Journal article

Journal

Biomaterials

Publication Date

01/2013

Volume

34

Pages

1146 - 1154

Keywords

Animals, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Breast Neoplasms, Cell Line, Tumor, Graphite, Humans, Mice, Mice, Inbred BALB C, Nanocapsules, Oxides, Pentetic Acid, Radiopharmaceuticals, Receptor, ErbB-2, Tomography, Emission-Computed, Single-Photon, Trastuzumab, Treatment Outcome